Revvity's Q4 revenue, adjusted EPS rise on diagnostics growth

Revvity

02/02/2026 11:09

Overview

Health science solutions provider's Q4 revenue grew 6% yr/yr to $772 mln

Adjusted EPS for Q4 rose to $1.70 from $1.42 yr/yr

Company initiates full year 2026 guidance, forecasting revenue of $2.96-$2.99 bln

Outlook

Revvity forecasts 2026 revenue between $2.96 bln and $2.99 bln

Company expects 2026 organic revenue growth of 2-3%

Revvity projects 2026 adjusted EPS of $5.35-$5.45

Result Drivers

DIAGNOSTICS GROWTH - Diagnostics segment revenue increased 10%, with 7% organic growth, aiding overall revenue growth

LIFE SCIENCES PERFORMANCE - Life Sciences segment showed 2% revenue growth, but organic revenue was flat

PORTFOLIO TRANSFORMATION - CEO cited portfolio transformation as positioning the company to capitalize on market conditions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
$0.87
Q4 Adjusted EPS continuing operations
$1.70


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Revvity Inc is $115.00, about 5.7% above its January 30 closing price of $108.80

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nBwkQl67a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)